SCHEDULE: Ayrton Capital Discloses 6.52% Stake in SeaStar Medical

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 6.52% beneficial ownership stake in SeaStar Medical Holding Corporation.

Summary

• Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri collectively report beneficial ownership of 278,436 shares of SeaStar Medical common stock.
• The reported shares are issuable upon the exercise of warrants held by the reporting persons.
• The stake represents 6.52% of the issuer's outstanding common stock as of March 31, 2026.
• The reporting persons certify that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure reflecting standard institutional portfolio activity without indicating a change in company fundamentals.

Positives

• Institutional investment interest from Ayrton Capital and associated entities indicates market confidence in the underlying asset.
• The filing confirms the reporting persons are passive investors, reducing concerns regarding immediate hostile takeover or activist intervention.

Negatives

• The beneficial ownership is derived entirely from warrants rather than direct equity, which may indicate a hedging or speculative strategy rather than long-term fundamental investment.
• The 9.99% beneficial ownership blocker on the warrants limits the immediate voting power of the reporting group.

Risks

• The investment is subject to the volatility of SeaStar Medical's common stock price.
• The value of the holding is contingent upon the exercise of warrants, which may be impacted by the issuer's future capital structure or stock performance.

Future Outlook

The reporting persons have stated they do not intend to influence or change the control of the issuer, suggesting a passive investment stance.

Management Comments

• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by investment firms in small-cap medical technology companies often signal liquidity provision or arbitrage strategies rather than long-term strategic partnerships.

Comparison to Industry Standards

• The filing follows standard regulatory requirements for institutional investors crossing the 5% ownership threshold.
• The use of a 9.99% ownership blocker is a standard protective measure in warrant-based investment agreements to avoid triggering change-of-control provisions.

Stakeholder Impact

• Shareholders should note the presence of a significant institutional holder, though the passive nature of the investment limits immediate strategic impact.

Next Steps

• The reporting persons will continue to monitor their position in accordance with SEC reporting requirements.

Key Dates

Keywords

SeaStar Medical, Schedule 13G, Ayrton Capital, Beneficial Ownership, Warrants, Institutional Investor